Lobeglitazone
 | |
| Clinical data | |
|---|---|
| Trade names | Duvie |
| Routes of administration | Oral |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Protein binding | >99%[1] |
| Metabolism | liver (CYP2C9, 2C19, and 1A2)[1] |
| Biological half-life | 7.8–9.8 hours[2] |
| Identifiers | |
| |
| Synonyms | CKD-501 |
| CAS Number | 607723-33-1 |
| PubChem (CID) | 9826451 |
| DrugBank |
DB09198  |
| ChemSpider | 8002194 |
| Chemical and physical data | |
| Formula | C24H24N4O5S |
| Molar mass | 480.53616 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
Lobeglitazone (trade name Duvie, Chong Kun Dang) is an antidiabetic drug in the thiazolidinedione class of drugs. As an agonist for both PPARα and PPARγ, it works as an insulin sensitizer by binding to the PPAR receptors in fat cells and making the cells more responsive to insulin.[3]
Medical uses
Lobeglitazone is used to assist regulation of blood glucose level of diabetes mellitus type 2 patients. It can be used alone or in combination with metformin.[4]
Lobeglitazone was approved by the Ministry of Food and Drug Safety (Korea) in 2013, and the postmarketing surveillance is on progress until 2019.[4][5]
References
- 1 2 Lee JH, Noh CK, Yim CS, Jeong YS, Ahn SH, Lee W, Kim DD, Chung SJ (2015). "Kinetics of the Absorption, Distribution, Metabolism, and Excretion of Lobeglitazone, a Novel Activator of Peroxisome Proliferator-Activated Receptor Gamma in Rats.". Journal of Pharmaceutical sciences. 104 (9): 3049–3059. doi:10.1002/jps.24378. PMID 25648999.
- ↑ Kim JW, Kim JR, Yi S, Shin KH, Shin HS, Yoon SH, Cho JY, Kim DH, Shin SG, Jang IJ, Yu KS (2011). "Tolerability and pharmacokinetics of lobeglitazone (CKD-501), a peroxisome proliferator-activated receptor-γ agonist: a single- and multiple-dose, double-blind, randomized control study in healthy male Korean subjects.". Clinical therapeutics. 33 (11): 1819–1830. doi:10.1016/j.clinthera.2011.09.023. PMID 22047812.
- ↑ Lee JH, Woo YA, Hwang IC, Kim CY, Kim DD, Shim CK, Chung SJ (2009). "Quantification of CKD-501, lobeglitazone, in rat plasma using a liquid-chromatography/tandem mass spectrometry method and its applications to pharmacokinetic studies.". Journal of Pharmaceutical and Biomedical Analysis. 50 (5): 872–877. doi:10.1016/j.jpba.2009.06.003. PMID 19577404.
- 1 2 "MFDS permission information of Duvie Tablet 0.5mg" (Release of Information). Ministry of Food and Drug Safety. Retrieved 2014-10-23.
- ↑ "국내개발 20번째 신약'듀비에정'허가(20th new drug developed in Korea 'Duvie Tablet' was approved)". Chong Kun Dang press release. 2013-07-04. Retrieved 2014-10-23.
This article is issued from Wikipedia - version of the 6/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.